Loading...

Christopher Kane

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentUrology
Address200 W. Arbor Drive #8897
San Diego CA 92103
Phone619-543-2626
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Christopher J. Kane is a specialist in prostate cancer and an expert in robotic and other minimally invasive procedures for urologic surgery.

    Named a 2017 “Top Doc" in San Diego Magazine’s “Physicians of Exceptional Excellence" annual survey performed in collaboration with the San Diego County Medical Society, Dr. Kane is internationally recognized for his patient care and research in prostate cancer, renal cell carcinoma, and minimally invasive surgical treatment of urologic diseases and disorders.

    Dr. Kane is an expert in robotic prostatectomy, open and laparoscopic kidney cancer surgery and bladder and testes cancer surgery. He has authored more than 220 publications and book chapters primarily on prostate cancer risk factors and outcomes, prostate cancer surgery and minimally invasive surgery for prostate and kidney cancer. He has taught laparoscopy and robotic surgery extensively and started the robotic surgery program at UC San Francisco and at the VA Medical Center San Francisco in 2002.

    He performs over 200 robotic cancer surgeries per year and is highly experienced in nerve sparing robotic prostatectomies, robotic radical cystectomy for bladder cancer and robotic partial nephrectomy for kidney cancer.

    To make an appointment with Dr. Kane, please call: 858-822-6187


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Cancer. 2018 Nov 14. PMID: 30427535.
      View in: PubMed
    2. Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ. Obesity, Risk of Biochemical Recurrence, and PSADT after Radical Prostatectomy: Results from the SEARCH Database. BJU Int. 2018 Oct 22. PMID: 30347135.
      View in: PubMed
    3. Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clin Genitourin Cancer. 2018 Oct 04. PMID: 30366879.
      View in: PubMed
    4. Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Oct 02. PMID: 30279582.
      View in: PubMed
    5. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 Sep 25. PMID: 30253446.
      View in: PubMed
    6. Hingorani DV, Whitney MA, Friedman B, Kwon JK, Crisp JL, Xiong Q, Gross L, Kane CJ, Tsien RY, Nguyen QT. Nerve-targeted probes for fluorescence-guided intraoperative imaging. Theranostics. 2018; 8(15):4226-4237. PMID: 30128049.
      View in: PubMed
    7. Bryant AK, D'Amico AV, Nguyen PL, Einck JP, Kane CJ, McKay RR, Simpson DR, Mundt AJ, Murphy JD, Rose BS. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Cancer. 2018 May 04. PMID: 29727915.
      View in: PubMed
    8. Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018 Jun; 29(6):581-588. PMID: 29663110.
      View in: PubMed
    9. Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 Apr 17. PMID: 29891203.
      View in: PubMed
    10. Orosco RK, Tapia VJ, Califano JA, Clary B, Cohen EEW, Kane C, Lippman SM, Messer K, Molinolo A, Murphy JD, Pang J, Sacco A, Tringale KR, Wallace A, Nguyen QT. Positive Surgical Margins in the 10 Most Common Solid Cancers. Sci Rep. 2018 Apr 09; 8(1):5686. PMID: 29632347.
      View in: PubMed
    11. Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Mar 09. PMID: 29521009.
      View in: PubMed
    12. Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ. Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Feb 23. PMID: 29473992.
      View in: PubMed
    13. McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urol Oncol. 2018 Feb 08. PMID: 29429895.
      View in: PubMed
    14. Leivo MZ, Sahoo D, Hamilton Z, Mirsadraei L, Shabaik A, Parsons JK, Kader AK, Derweesh I, Kane C, Hansel DE. Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. Am J Surg Pathol. 2018 Jan; 42(1):e1-e10. PMID: 29076872.
      View in: PubMed
    15. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. PMID: 29236593.
      View in: PubMed
    16. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 Feb 20; 36(6):581-590. PMID: 29185869.
      View in: PubMed
    17. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate. 2017 Dec; 77(16):1592-1600. PMID: 28994485.
      View in: PubMed
    18. Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. J Urol. 2017 Sep 01. PMID: 28870860.
      View in: PubMed
    19. Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Oct; 108:129-134. PMID: 28735016.
      View in: PubMed
    20. Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol. 2018 Jan; 199(1):53-59. PMID: 28728992.
      View in: PubMed
    21. Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017 Dec; 198(6):1309-1315. PMID: 28709888.
      View in: PubMed
    22. Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ. Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. Int J Urol. 2017 Aug; 24(8):618-623. PMID: 28697533.
      View in: PubMed
    23. Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Nov 01; 123(21):4122-4129. PMID: 28662291.
      View in: PubMed
    24. Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer. 2017 Nov 01; 123(21):4199-4206. PMID: 28654204.
      View in: PubMed
    25. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2017 Aug; 24(8):611-617. PMID: 28589550.
      View in: PubMed
    26. Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 Nov; 72(5):845-852. PMID: 28528811.
      View in: PubMed
    27. Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 11; 120(5B):E80-E86. PMID: 28371163.
      View in: PubMed
    28. Kane CJ, Eggener SE, Shindel AW, Andriole GL. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 Oct; 3(4-5):487-497. PMID: 28753804.
      View in: PubMed
    29. Lee HJ, Barback CV, Hoh CK, Qin Z, Kader K, Hall DJ, Vera DR, Kane CJ. Fluorescence-Based Molecular Imaging of Porcine Urinary Bladder Sentinel Lymph Nodes. J Nucl Med. 2017 Apr; 58(4):547-553. PMID: 28153955.
      View in: PubMed
    30. Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017 05 01; 123(9):1528-1535. PMID: 28026865.
      View in: PubMed
    31. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate. 2017 Feb; 77(2):154-163. PMID: 27683213.
      View in: PubMed
    32. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. PMID: 27688020.
      View in: PubMed
    33. Hirata T, Park SC, Muldong MT, Wu CN, Yamaguchi T, Strasner A, Raheem O, Kumon H, Sah RL, Cacalano NA, Jamieson CHM, Kane CJ, Masuda K, Kulidjian AA, Jamieson CAM. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian J Urol. 2016 Oct; 3(4):229-239. PMID: 29264191.
      View in: PubMed
    34. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clin Genitourin Cancer. 2017 02; 15(1):60-66.e2. PMID: 27692812.
      View in: PubMed
    35. Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. Eur Urol Focus. 2017 Oct; 3(4-5):480-486. PMID: 28753787.
      View in: PubMed
    36. Brunsing RL, Schenker-Ahmed NM, White NS, Parsons JK, Kane C, Kuperman J, Bartsch H, Kader AK, Rakow-Penner R, Seibert TM, Margolis D, Raman SS, McDonald CR, Farid N, Kesari S, Hansel D, Shabaik A, Dale AM, Karow DS. Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. J Magn Reson Imaging. 2017 Feb; 45(2):323-336. PMID: 27527500.
      View in: PubMed
    37. Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Dec 15; 122(24):3848-3855. PMID: 27505036.
      View in: PubMed
    38. Lee HJ, Yousefi K, Haddad Z, Abdollah F, Lam LL, Shin H, Alshalalfa M, Godebu E, Wang S, Shabaik A, Davicioni E, Kane CJ. Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Res Rep Urol. 2016; 8:77-84. PMID: 27419104; PMCID: PMC4935177.
    39. Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 Nov; 196(5):1408-1414. PMID: 27352635.
      View in: PubMed
    40. McDonald ML, Liss MA, Nseyo UU, Gal DB, Kane CJ, Kader AK. Weight Loss Following Radical Cystectomy for Bladder Cancer: Characterization and Effect on Survival. Clin Genitourin Cancer. 2017 02; 15(1):86-92. PMID: 27460433.
      View in: PubMed
    41. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016 Oct; 96:171-176. PMID: 27318265.
      View in: PubMed
    42. Yamin G, Schenker-Ahmed NM, Shabaik A, Adams D, Bartsch H, Kuperman J, White NS, Rakow-Penner RA, McCammack K, Parsons JK, Kane CJ, Dale AM, Karow DS. Voxel Level Radiologic-Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer. Clin Cancer Res. 2016 Jun 01; 22(11):2668-74. PMID: 27250935; PMCID: PMC4896066 [Available on 06/01/17].
    43. Hamilton Z, Lee HJ, Jimenez J, Lane BR, Wang S, Beksac AT, Gillis K, Alagh A, Tobert C, Randall JM, Kane CJ, Millard F, Campbell SC, Derweesh IH. Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. BJU Int. 2016 Dec; 118(6):927-934. PMID: 27008916.
      View in: PubMed
    44. McCammack KC, Schenker-Ahmed NM, White NS, Best SR, Marks RM, Heimbigner J, Kane CJ, Parsons JK, Kuperman JM, Bartsch H, Desikan RS, Rakow-Penner RA, Liss MA, Margolis DJ, Raman SS, Shabaik A, Dale AM, Karow DS. Restriction spectrum imaging improves MRI-based prostate cancer detection. Abdom Radiol (NY). 2016 05; 41(5):946-53. PMID: 26910114.
      View in: PubMed
    45. Patel N, Woo J, Liss MA, Palazzi KL, Randall JM, Mehrazin R, Jabaj R, Mirheydar HS, Gillis K, Lee HJ, Patterson AL, Kane CJ, Millard F, Derweesh IH. Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches. Can J Urol. 2016 Apr; 23(2):8227-33. PMID: 27085828.
      View in: PubMed
    46. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16. PMID: 26969090; PMCID: PMC4878938 [Available on 05/14/17].
    47. Gaylis F, Cohen E, Calabrese R, Prime H, Dato P, Kane CJ. Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve? Urology. 2016 07; 93:60-7. PMID: 26876460.
      View in: PubMed
    48. Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int. 2016 Oct; 118(4):570-7. PMID: 26762961.
      View in: PubMed
    49. Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):547-54. PMID: 26809276; PMCID: PMC4779730 [Available on 03/01/17].
    50. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 Jan; 14(1):19-30. PMID: 26733552.
      View in: PubMed
    51. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2016 Mar; 23(3):241-6. PMID: 26667212.
      View in: PubMed
    52. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15; 122(2):222-9. PMID: 26484853.
      View in: PubMed
    53. Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 2016 08; 118(2):250-7. PMID: 26351095.
      View in: PubMed
    54. Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. Cancer Epidemiol. 2015 Dec; 39(6):1066-70. PMID: 26452418.
      View in: PubMed
    55. Hamilton ZA, Kane CJ. Nerve-sparing Technique During Radical Prostatectomy and its Effect on Urinary Continence. Eur Urol. 2016 Apr; 69(4):590-1. PMID: 26320380.
      View in: PubMed
    56. Rakow-Penner RA, White NS, Margolis DJA, Parsons JK, Schenker-Ahmed N, Kuperman JM, Bartsch H, Choi HW, Bradley WG, Shabaik A, Huang J, Liss MA, Marks L, Kane CJ, Reiter RE, Raman SS, Karow DS, Dale AM. Prostate diffusion imaging with distortion correction. Magn Reson Imaging. 2015 Nov; 33(9):1178-1181. PMID: 26220859; PMCID: PMC4594204 [Available on 11/01/16].
    57. Liss MA, Kane CJ, Chen T, Baumgartner J, Derweesh IH. Virtual reality suturing task as an objective test for robotic experience assessment. BMC Urol. 2015 Jul 03; 15:63. PMID: 26137869; PMCID: PMC4490698.
    58. Raheem OA, Cohen SA, Parsons JK, Palazzi KL, Kane CJ. A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy. Sci Rep. 2015 Jun 26; 5:10544. PMID: 26112134; PMCID: PMC4481640.
    59. Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int. 2016 06; 117(6):897-903. PMID: 26010251.
      View in: PubMed
    60. Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. BJU Int. 2016 Feb; 117(2):244-8. PMID: 26010160; PMCID: PMC4658317 [Available on 02/01/17].
    61. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul; 33(7):329.e1-6. PMID: 25998746.
      View in: PubMed
    62. Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res. 2015 Sep 15; 21(18):4048-54. PMID: 25967143; PMCID: PMC4573791.
    63. Zelones J, Kiyama L, Sandler BJ, Kane CJ. Sigmoid perforation due to toothpick ingestion leading to hydronephrosis and urosepsis. Am Surg. 2015 May; 81(5):E232-3. PMID: 25975321.
      View in: PubMed
    64. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015 May 07; 521(7550):94-8. PMID: 25924065; PMCID: PMC4501632.
    65. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Jul; 22(7):658-62. PMID: 25872110.
      View in: PubMed
    66. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6. PMID: 25728968.
      View in: PubMed
    67. Liss MA, White NS, Parsons JK, Schenker-Ahmed NM, Rakow-Penner R, Kuperman JM, Bartsch H, Choi HW, Mattrey RF, Bradley WG, Shabaik A, Huang J, Margolis DJ, Raman SS, Marks LS, Kane CJ, Reiter RE, Dale AM, Karow DS. MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Front Oncol. 2015; 5:30. PMID: 25741473; PMCID: PMC4330697.
    68. Cartledge JE, Kane C, Dias P, Tesfom M, Clarke L, Mckee B, Al Ayoubi S, Chester A, Yacoub MH, Camelliti P, Terracciano CM. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res. 2015 Mar 01; 105(3):260-70. PMID: 25560320.
      View in: PubMed
    69. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015 May 01; 121(9):1414-21. PMID: 25492369; PMCID: PMC4409453.
    70. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. J Urol. 2015 Apr; 193(4):1232-8. PMID: 25463986.
      View in: PubMed
    71. Mirheydar HS, Banapour P, Massoudi R, Palazzi KL, Jabaji R, Reid EG, Millard FE, Kane CJ, Sur RL. What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders? Int Braz J Urol. 2014 Nov-Dec; 40(6):772-80. PMID: 25615245.
      View in: PubMed
    72. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56. PMID: 25304929; PMCID: PMC4221498.
    73. Lee HJ, Kane CJ. How to minimize lymphoceles and treat clinically symptomatic lymphoceles after radical prostatectomy. Curr Urol Rep. 2014 Oct; 15(10):445. PMID: 25129450.
      View in: PubMed
    74. White NS, McDonald C, McDonald CR, Farid N, Kuperman J, Karow D, Schenker-Ahmed NM, Bartsch H, Rakow-Penner R, Holland D, Shabaik A, Bjørnerud A, Hope T, Hattangadi-Gluth J, Liss M, Parsons JK, Chen CC, Raman S, Margolis D, Reiter RE, Marks L, Kesari S, Mundt AJ, Kane CJ, Kaine CJ, Carter BS, Bradley WG, Dale AM. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. Cancer Res. 2014 Sep 01; 74(17):4638-52. PMID: 25183788; PMCID: PMC4155409.
    75. Liss MA, Stroup SP, Qin Z, Hoh CK, Hall DJ, Vera DR, Kane CJ. Robotic-assisted fluorescence sentinel lymph node mapping using multimodal image guidance in an animal model. Urology. 2014 Oct; 84(4):982.e9-14. PMID: 25139676; PMCID: PMC4366424.
    76. Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol. 2015 Jan; 193(1):75-9. PMID: 25066872.
      View in: PubMed
    77. Bagrodia A, Kopp RP, Mehrazin R, Lee HJ, Liss MA, Jabaji R, Kane CJ, Wake RW, Patterson AL, Wan JY, Derweesh IH. Impact of renal surgery for cortical neoplasms on lipid metabolism. BJU Int. 2014 Dec; 114(6):837-43. PMID: 24656182.
      View in: PubMed
    78. Liss MA, Farshchi-Heydari S, Qin Z, Hickey SA, Hall DJ, Kane CJ, Vera DR. Preclinical evaluation of robotic-assisted sentinel lymph node fluorescence imaging. J Nucl Med. 2014 Sep; 55(9):1552-6. PMID: 25024425; PMCID: PMC4350927.
    79. Godebu E, Woldrich JM, Cohen SA, Kane CJ, Owens EL, Sakamoto K. Incorporating robot-assisted prostatectomy at a Veterans Affairs hospital: outcomes. J Endourol. 2014 Sep; 28(9):1097-102. PMID: 24819015.
      View in: PubMed
    80. Cohen SA, Mirheydar HS, Parsons JK, Palazzi KL, Liss MA, Chang DC, Kane CJ, Kader AK. Minimally invasive cystectomy is associated with improved perioperative patient safety outcomes compared with open cystectomy in a national cohort. Urology. 2014 Aug; 84(2):314-9. PMID: 24958477.
      View in: PubMed
    81. Cohen SA, Mirheydar HS, Parsons JK, Palazzi KL, Liss MA, Chang DC, Kane CJ, Kader AK. Reply: To PMID 24958477. Urology. 2014 Aug; 84(2):319-20. PMID: 24958489.
      View in: PubMed
    82. Kane CJ. Editorial comment. Urology. 2014 Jun; 83(6):1367-8. PMID: 24862396.
      View in: PubMed
    83. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014 Nov; 114(5):661-6. PMID: 24588774; PMCID: PMC4153797.
    84. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. PMID: 24812137.
      View in: PubMed
    85. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 01; 120(11):1656-62. PMID: 24647966.
      View in: PubMed
    86. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014 Jan 30; 12:30. PMID: 24475900; PMCID: PMC3914187.
    87. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014 Jan 15; 120(2):197-204. PMID: 24127391; PMCID: PMC4149056.
    88. Woo JR, Liss MA, Kane CJ. Laparoscopic removal of spermatic cord to reduce incision size of open retroperitoneal lymph node dissection. Urology. 2013 Oct; 82(4):959-62. PMID: 24074990.
      View in: PubMed
    89. Qin Z, Hall DJ, Liss MA, Hoh CK, Kane CJ, Wallace AM, Vera DR. Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes. J Biomed Opt. 2013 Oct; 18(10):101315. PMID: 23958947; PMCID: PMC3745642.
    90. Cohen SA, Kane CJ, Juwono T, Masterson JH, Kaplan GW. Urology in San Diego--its history in "America's finest city". Urology. 2013 Aug; 82(2):280-3. PMID: 23896091.
      View in: PubMed
    91. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. Urology. 2013 Jul; 82(1):53-8. PMID: 23806388; PMCID: PMC3774016.
    92. Bazzi WM, Stroup SP, Cohen SA, Sisul DM, Liss MA, Masterson JH, Kopp RP, Gudeman SR, Leeflang E, Palazzi KL, Ramamoorthy S, Kane CJ, Horgan S, Derweesh IH. Comparison of transrectal and transvaginal hybrid natural orifice transluminal endoscopic surgery partial nephrectomy in the porcine model. Urology. 2013 Jul; 82(1):84-9. PMID: 23676357.
      View in: PubMed
    93. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: results from the SEARCH Database. Int Braz J Urol. 2013 May-Jun; 39(3):312-8; discussion 319. PMID: 23849564.
      View in: PubMed
    94. Kane CJ, Liss MA. Prostate cancer: risk versus benefit of lymph node dissection during prostatectomy. Nat Rev Urol. 2013 May; 10(5):262-3. PMID: 23609844.
      View in: PubMed
    95. Kane CJ, Kader AK. Guest editorial: robotic techniques in urologic oncology. World J Urol. 2013 Jun; 31(3):429. PMID: 23595604.
      View in: PubMed
    96. Liss MA, Kane CJ. Editorial comment from Dr Liss and Dr Kane to lymphocele after extraperitoneal robot-assisted radical prostatectomy: a propensity score-matching study. Int J Urol. 2013 Dec; 20(12):1177. PMID: 23586475.
      View in: PubMed
    97. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7. PMID: 23587869.
      View in: PubMed
    98. Liss MA, Palazzi K, Stroup SP, Jabaji R, Raheem OA, Kane CJ. Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy. World J Urol. 2013 Jun; 31(3):481-8. PMID: 23512231.
      View in: PubMed
    99. Stroup SP, Raheem OA, Palazzi KL, Liss MA, Mehrazin R, Kopp RP, Patel N, Cohen SA, Park SK, Patterson AL, Kane CJ, Millard F, Derweesh IH. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. Urology. 2013 Apr; 81(4):805-11. PMID: 23414694.
      View in: PubMed
    100. Kane C. Commentary on "impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy." Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salomon L, de la Taille A, Institut National de la Sante et de la Recherche Medicale Unit 955 EQ7, Department of Urology, APHP, CHU Henri Mondor, Créteil, France: Urology 2012;80(3):576-84. Urol Oncol. 2013 Feb; 31(2):274-5. PMID: 23465475.
      View in: PubMed
    101. Kane C. Commentary on "applicability of robot-assisted laparoscopic radical prostatectomy in renal allograft recipients." Wagener N, Nyarangi-Dix JN, Teber D, Zeier M, Hohenfellner M, Department of Urology, University of Heidelberg, Heidelberg, Germany: Transplant Proc 2012; 44(5):1287-92. Urol Oncol. 2013 Feb; 31(2):272. PMID: 23465472.
      View in: PubMed
    102. Kane C. Commentary on "anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: A prospective randomized multicentre trial." Hurtes X, Rouprêt M, Vaessen C, Pereira H, d'Arcier BF, Cormier L, Bruyère F, Urology Department, University Hospital of Tours, Tours, France: BJU Int 2012;110(6):875-83. Urol Oncol. 2013 Feb; 31(2):272-3. PMID: 23465473.
      View in: PubMed
    103. Kane C. Commentary on "salvage laparoscopic radical prostatectomy following high-intensity focused ultrasound for treatment of prostate cancer." Leonardo L, Franco G, De Nunzio C, Tubaro A, Salvitti M, Tartaglia N, Simonelli G, De Dominicis C, Department of Urology, La Sapienza University of Rome, Italy: Urology 2012;80(1):130-3. Urol Oncol. 2013 Feb; 31(2):273-4. PMID: 23465474.
      View in: PubMed
    104. Kane C. Commentary on "a matched comparison of perioperative outcomes of a single laparoscopic surgeon versus a multisurgeon robot-assisted cohort for partial nephrectomy." Ellison JS, Montgomery JS, Wolf Jr JS, Hafez KS, Miller DC, Weizer AZ, Department of Urology, University of Michigan, Ann Arbor, MI, USA: J Urol 2012;188(1):45-50. Urol Oncol. 2013 Feb; 31(2):275. PMID: 23465477.
      View in: PubMed
    105. Wu C, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU Int. 2013 Jun; 111(8):E310-8. PMID: 23305170.
      View in: PubMed
    106. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol. 2014 Mar; 65(3):620-7. PMID: 23245686; PMCID: PMC3634863.
    107. Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013 Mar; 73(4):409-17. PMID: 22996686.
      View in: PubMed
    108. Bazzi WM, Stroup SP, Cohen SA, Dotai T, Kopp RP, Colangelo C, Raheem OA, Ramamoorthy S, Talamini M, Horgan S, Kane CJ, Derweesh IH. Feasibility of transrectal hybrid natural orifice transluminal endoscopic surgery (NOTES) nephrectomy in the cadaveric model. Urology. 2012 Sep; 80(3):590-5. PMID: 22925236.
      View in: PubMed
    109. Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol. 2012 Nov; 62(5):910-6. PMID: 22921964; PMCID: PMC3500618.
    110. Kopp RP, Dicks BM, Goldstein I, Mehrazin R, Silberstein JL, Colangelo CJ, Bagrodia A, Bazzi WM, Wake RW, Patterson AL, Kane CJ, Wan JY, Derweesh IH. Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis. BJU Int. 2013 Mar; 111(3 Pt B):E98-102. PMID: 22757628.
      View in: PubMed
    111. Emerson DK, Limmer KK, Hall DJ, Han SH, Eckelman WC, Kane CJ, Wallace AM, Vera DR. A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging. Radiology. 2012 Oct; 265(1):186-93. PMID: 22753678; PMCID: PMC3447170.
    112. Kane CJ. Robotic prostatectomy improves outcomes--after the potentially risky adoption phase. Oncology (Williston Park). 2012 Jul; 26(7):626, 628, 630. PMID: 22888562.
      View in: PubMed
    113. Stroup SP, Kane CJ, Farchshchi-Heydari S, James CM, Davis CH, Wallace AM, Hoh CK, Vera DR. Preoperative sentinel lymph node mapping of the prostate using PET/CT fusion imaging and Ga-68-labeled tilmanocept in an animal model. Clin Exp Metastasis. 2012 Oct; 29(7):673-80. PMID: 22714690.
      View in: PubMed
    114. Raheem OA, Bazzi WM, Parsons JK, Kane CJ. Management of pelvic lymphoceles following robot-assisted laparoscopic radical prostatectomy. Urol Ann. 2012 May; 4(2):111-4. PMID: 22629010; PMCID: PMC3355695.
    115. Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC, Amling CL, Kane CJ. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. J Urol. 2012 Jun; 187(6):2056-60. PMID: 22498218; PMCID: PMC3409579.
    116. Muller RL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. Urology. 2012 May; 79(5):1105-10. PMID: 22446345; PMCID: PMC3431014.
    117. Chu DI, Moreira DM, Gerber L, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2012 Oct 15; 118(20):4999-5007. PMID: 22415377; PMCID: PMC3376692.
    118. Nowfar S, Kopp R, Palazzi-Churas K, Derweesh IH, Kane CJ. Initial experience with aspirin use during robotic radical prostatectomy. J Laparoendosc Adv Surg Tech A. 2012 Apr; 22(3):225-9. PMID: 22393926.
      View in: PubMed
    119. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2012 Aug; 110(4):492-8. PMID: 22094083; PMCID: PMC3343219.
    120. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28; 9:185. PMID: 22035283; PMCID: PMC3269442.
    121. Stroup SP, Kane CJ. Robotic-assisted laparoscopic prostatectomy for high-risk prostate cancer: technical considerations and review of the literature. ISRN Urol. 2011; 2011:201408. PMID: 22084791; PMCID: PMC3196353.
    122. Woldrich J, Mehrazin R, Bazzi WM, Bagrodia A, Kopp RP, Malcolm JB, Kane CJ, Patterson AL, Wan JY, Derweesh IH. Comparison of rates and risk factors for development of anaemia and erythropoiesis-stimulating agent utilization after radical or partial nephrectomy. BJU Int. 2012 Apr; 109(7):1019-25. PMID: 21933323.
      View in: PubMed
    123. Mohr SB, Gorham ED, Alcaraz JE, Kane CJ, Macera CA, Parsons JK, Wingard DL, Garland CF. Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res. 2011 Sep; 31(9):2939-48. PMID: 21868542.
      View in: PubMed
    124. Bazzi WM, Raheem OA, Stroup SP, Kane CJ, Derweesh IH, Downs TM. Partial orchiectomy and testis intratubular germ cell neoplasia: World literature review. Urol Ann. 2011 Sep; 3(3):115-8. PMID: 21976922; PMCID: PMC3183701.
    125. Kane CJ, Raheem OA, Bent S, Avins AL. What do I tell patients about saw palmetto for benign prostatic hyperplasia? Urol Clin North Am. 2011 Aug; 38(3):261-77. PMID: 21798388.
      View in: PubMed
    126. Bagrodia A, Mehrazin R, Bazzi WM, Silberstein J, Malcolm JB, Stroup SP, Raheem O, Wake RW, Kane CJ, Patterson AL, Wan JY, Derweesh IH. Comparison of rates and risk factors for development of osteoporosis and fractures after radical or partial nephrectomy. Urology. 2011 Sep; 78(3):614-9. PMID: 21777959.
      View in: PubMed
    127. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9. PMID: 21679982.
      View in: PubMed
    128. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group. Urology. 2011 Jan; 77(1):149-53. PMID: 21145094; PMCID: PMC3051841.
    129. Breyer BN, Davis CB, Cowan JE, Kane CJ, Carroll PR. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int. 2010 Dec; 106(11):1734-8. PMID: 20438567; PMCID: PMC3565608.
    130. Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010 Nov; 106(9):1270-6. PMID: 20394613.
      View in: PubMed
    131. Kim HS, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate. 2010 Oct 01; 70(14):1540-6. PMID: 20687228; PMCID: PMC2930134.
    132. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, Freedland SJ. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol. 2010 Nov; 17(11):914-22. PMID: 20880361; PMCID: PMC3188446.
    133. Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011 Mar; 107(6):924-8. PMID: 20860651; PMCID: PMC3055926.
    134. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010 Jul 15; 116(14):3389-98. PMID: 20586112; PMCID: PMC3188453.
    135. Derweesh IH, Silberstein JL, Bazzi W, Kopp R, Downs TM, Kane CJ. Laparo-endoscopic single-site surgery for radical and cytoreductive nephrectomy, renal vein thrombectomy, and partial nephrectomy: a prospective pilot evaluation. Diagn Ther Endosc. 2010; 2010:107482. PMID: 20631830; PMCID: PMC2901611.
    136. Kane CJ, Im R, Amling CL, Presti JC, Aronson WJ, Terris MK, Freedland SJ. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010 Sep; 76(3):695-700. PMID: 20394969; PMCID: PMC2939285.
    137. Moreira DM, Antonelli JA, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2010 Nov; 76(5):1218-23. PMID: 20381838; PMCID: PMC3177236.
    138. Jayachandran J, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):9-17. PMID: 20056618; PMCID: PMC2805474.
    139. Nath SK, Sandhu AP, Rose BS, Simpson DR, Nobiensky PD, Wang JZ, Millard F, Kane CJ, Parsons JK, Mundt AJ. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Oct 01; 78(2):435-41. PMID: 19939580.
      View in: PubMed
    140. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009 Nov 15; 115(22):5263-71. PMID: 19670453; PMCID: PMC2783966.
    141. Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int. 2010 Jun; 105(12):1654-9. PMID: 19912203.
      View in: PubMed
    142. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2010 Jun; 105(11):1541-7. PMID: 19912191.
      View in: PubMed
    143. Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology. 2010 Feb; 75(2):439-44. PMID: 19819536.
      View in: PubMed
    144. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009 Nov; 182(5):2250-5. PMID: 19758614.
      View in: PubMed
    145. Kane CJ, Dicks B. Editorial comment. Urology. 2009 Sep; 74(3):617-8. PMID: 19716915.
      View in: PubMed
    146. Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU Int. 2010 Feb; 105(3):347-51. PMID: 19709073.
      View in: PubMed
    147. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int. 2009 Dec; 104(11):1604-9. PMID: 19549124.
      View in: PubMed
    148. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92. PMID: 19549119.
      View in: PubMed
    149. Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug; 182(2):491-6; discussion 496-8. PMID: 19524974.
      View in: PubMed
    150. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2010 Jan; 105(1):28-33. PMID: 19522861.
      View in: PubMed
    151. Moreira DM, Jayachandran J, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, Freedland SJ. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2009 Nov; 104(10):1452-6. PMID: 19466946.
      View in: PubMed
    152. Bañez LL, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Freedland SJ. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2009 Apr; 18(4):1208-12. PMID: 19336564; PMCID: PMC3179689.
    153. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Terris MK. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int. 2009 May; 103(9):1168-72. PMID: 19298411; PMCID: PMC3179688.
    154. Silberstein J, Grabowski J, Saltzstein SL, Kane CJ. Renal cell carcinoma in the pediatric population: Results from the California Cancer Registry. Pediatr Blood Cancer. 2009 Feb; 52(2):237-41. PMID: 18937317.
      View in: PubMed
    155. Schroeck FR, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int. 2009 Mar; 103(5):603-8. PMID: 19021608; PMCID: PMC2753544.
    156. Teeter AE, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol. 2008 Nov; 180(5):1980-4; discussion 1985. PMID: 18801519; PMCID: PMC3182520.
    157. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, Freedland SJ. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU Int. 2008 Nov; 102(9):1074-9. PMID: 18778348; PMCID: PMC3186764.
    158. Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008 Sep; 102(8):969-74. PMID: 18691175.
      View in: PubMed
    159. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2008 Sep; 102(8):964-8. PMID: 18691176; PMCID: PMC3175752.
    160. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008 Jul 01; 113(1):78-83. PMID: 18491376.
      View in: PubMed
    161. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. PMID: 18433013.
      View in: PubMed
    162. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008 Jun; 179(6):2131-5. PMID: 18423754.
      View in: PubMed
    163. Dall'Era MA, Kane CJ. Watchful waiting versus active surveillance: appropriate patient selection. Curr Urol Rep. 2008 May; 9(3):211-6. PMID: 18765115.
      View in: PubMed
    164. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol. 2008 May; 179(5):1709-13; discussion 1713. PMID: 18343430.
      View in: PubMed
    165. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May; 179(5):1785-9; discussion 1789-90. PMID: 18343434; PMCID: PMC3179690.
    166. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May; 179(5):1791-6; discussion 1796. PMID: 18343426; PMCID: PMC3179686.
    167. Avins AL, Bent S, Staccone S, Badua E, Padula A, Goldberg H, Neuhaus J, Hudes E, Shinohara K, Kane C. A detailed safety assessment of a saw palmetto extract. Complement Ther Med. 2008 Jun; 16(3):147-54. PMID: 18534327; PMCID: PMC2518869.
    168. Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR, Kane CJ. Effect of BMI on primary treatment of prostate cancer. Urology. 2008 Aug; 72(2):406-11. PMID: 18267336.
      View in: PubMed
    169. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, Freedland SJ. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol. 2008 Feb; 179(2):523-7; discussion 527-8. PMID: 18076952.
      View in: PubMed
    170. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Urology. 2008 Jan; 71(1):151-5. PMID: 18242385.
      View in: PubMed
    171. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21; 298(19):2275-80. PMID: 18029831.
      View in: PubMed
    172. Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007 Nov 15; 110(10):2202-9. PMID: 17876838.
      View in: PubMed
    173. Ku TS, Kane CJ, Sen S, Henderson WG, Dudley RA, Cason BA. Effects of hospital procedure volume and resident training on clinical outcomes and resource use in radical retropubic prostatectomy surgery in the Department of Veterans Affairs. J Urol. 2008 Jan; 179(1):272-8; discussion 278-9. PMID: 18001784.
      View in: PubMed
    174. Buschemeyer WC, Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. J Urol. 2008 Jan; 179(1):124-9; discussion 129. PMID: 17997433.
      View in: PubMed
    175. Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database. Eur Urol. 2008 Apr; 53(4):758-64; discussion 765-6. PMID: 17868976.
      View in: PubMed
    176. Scales CD, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. J Urol. 2007 Oct; 178(4 Pt 1):1249-52. PMID: 17698131.
      View in: PubMed
    177. Kang DE, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology. 2007 Aug; 70(2):277-82. PMID: 17826489; PMCID: PMC3275808.
    178. Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ, Presti JC, Aronson WJ, Freedland SJ. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol. 2007 Sep; 178(3 Pt 1):990-5. PMID: 17632170.
      View in: PubMed
    179. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, Presti JC, Mangold LA, Freedland SJ. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007 Jun; 69(6):1138-42. PMID: 17572202; PMCID: PMC3275802.
    180. Joudi FN, Allareddy V, Kane CJ, Konety BR. Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. J Urol. 2007 May; 177(5):1709-14. PMID: 17437791.
      View in: PubMed
    181. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. Urology. 2007 May; 69(5):921-6. PMID: 17482935.
      View in: PubMed
    182. Knight SJ, Latini DM, Hart SL, Sadetsky N, Kane CJ, DuChane J, Carroll PR. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer. 2007 May 01; 109(9):1769-76. PMID: 17380491.
      View in: PubMed
    183. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology. 2007 Apr; 69(4):732-7. PMID: 17445660.
      View in: PubMed
    184. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology. 2007 Mar; 69(3):495-9. PMID: 17382152; PMCID: PMC3080253.
    185. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007 Mar; 177(3):883-7; discussion 887-8. PMID: 17296367.
      View in: PubMed
    186. Kane CJ, Presti JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ. Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007 Jan; 177(1):113-7. PMID: 17162017.
      View in: PubMed
    187. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF, DuChane J, Carroll PR. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Urology. 2006 Dec; 68(6):1242-7. PMID: 17141841.
      View in: PubMed
    188. Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol. 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PMID: 17085127.
      View in: PubMed
    189. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91. PMID: 17039503.
      View in: PubMed
    190. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006 Sep 15; 107(6):1265-72. PMID: 16900523.
      View in: PubMed
    191. Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol. 2006 Jul; 20(7):504-8. PMID: 16859465.
      View in: PubMed
    192. Ross PL, Meng MV, Kane CJ. Laparoscopic approaches to renal malignancies. Curr Probl Cancer. 2006 Jul-Aug; 30(4):168-93. PMID: 16860165.
      View in: PubMed
    193. Camargo AH, Rubenstein JN, Ershoff BD, Meng MV, Kane CJ, Stoller ML. The effect of kidney morcellation on operative time, incision complications, and postoperative analgesia after laparoscopic nephrectomy. Int Braz J Urol. 2006 May-Jun; 32(3):273-9; discussion 279-80. PMID: 16813669.
      View in: PubMed
    194. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Terris MK. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006 Apr; 175(4):1298-302; discussion 1302-3. PMID: 16515984.
      View in: PubMed
    195. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006 Feb 09; 354(6):557-66. PMID: 16467543.
      View in: PubMed
    196. Freedland SJ, Platz EA, Presti JC, Aronson WJ, Amling CL, Kane CJ, Terris MK. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006 Feb; 175(2):500-4; discussion 504. PMID: 16406980.
      View in: PubMed
    197. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer. 2006 Jan 01; 106(1):79-86. PMID: 16323173.
      View in: PubMed
    198. Greene KL, Elkin EP, Karapetian A, Duchane J, Carroll PR, Kane CJ. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE. J Urol. 2006 Jan; 175(1):125-9; discussion 129. PMID: 16406887.
      View in: PubMed
    199. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005 Nov; 66(5):1060-5. PMID: 16286124.
      View in: PubMed
    200. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC, Terris MK. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. Clin Cancer Res. 2005 Nov 01; 11(21):7735-42. PMID: 16278394.
      View in: PubMed
    201. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC, Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005 Oct 20; 23(30):7546-54. PMID: 16234520.
      View in: PubMed
    202. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene. 2005 Oct 13; 24(45):6765-72. PMID: 16007175.
      View in: PubMed
    203. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6582-8. PMID: 16166436.
      View in: PubMed
    204. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005 Aug 20; 116(2):174-81. PMID: 15800905.
      View in: PubMed
    205. Master VA, Gottschalk AR, Kane C, Carroll PR. Management of isolated renal fossa recurrence following radical nephrectomy. J Urol. 2005 Aug; 174(2):473-7; discussion 477. PMID: 16006867.
      View in: PubMed
    206. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 2005 Jul 01; 104(1):44-52. PMID: 15895377.
      View in: PubMed
    207. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005 Apr; 173(4):1132-8. PMID: 15758721.
      View in: PubMed
    208. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr; 173(4):1126-31. PMID: 15758720.
      View in: PubMed
    209. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005 Mar; 173(3):732-6. PMID: 15711258.
      View in: PubMed
    210. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):557-64. PMID: 15701841.
      View in: PubMed
    211. Kawakami T, Shiina H, Igawa M, Deguchi M, Nakajima K, Ogishima T, Tokizane T, Urakami S, Enokida H, Miura K, Ishii N, Kane CJ, Carroll PR, Dahiya R. Inactivation of the hMSH3 mismatch repair gene in bladder cancer. Biochem Biophys Res Commun. 2004 Dec 17; 325(3):934-42. PMID: 15541380.
      View in: PubMed
    212. Anast JW, Stoller ML, Meng MV, Master VA, Mitchell JA, Bassett WW, Kane CJ. Differences in complications and outcomes for obese patients undergoing laparoscopic radical, partial or simple nephrectomy. J Urol. 2004 Dec; 172(6 Pt 1):2287-91. PMID: 15538250.
      View in: PubMed
    213. Zhao H, Li LC, Okino ST, Kane CJ, Carroll PR, Dahiya R. Kidney gene database: a curated and integrated database of genes involved in kidney disease. J Urol. 2004 Dec; 172(6 Pt 1):2344-6. PMID: 15538263.
      View in: PubMed
    214. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004 Sep 01; 64(17):5956-62. PMID: 15342374.
      View in: PubMed
    215. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ, Carroll PR, Igawa M, Dahiya R. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun. 2004 Aug 20; 321(2):455-61. PMID: 15358197.
      View in: PubMed
    216. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC, Trock B, Amling CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004 Aug 15; 101(4):748-53. PMID: 15305405.
      View in: PubMed
    217. Chen H, Ng V, Kane CJ, Russell IA. The role of transesophageal echocardiography in rapid diagnosis and treatment of migratory tumor embolus. Anesth Analg. 2004 Aug; 99(2):357-9, table of contents. PMID: 15271705.
      View in: PubMed
    218. Freedland SJ, Terris MK, Presti JC, Amling CL, Kane CJ, Trock B, Aronson WJ. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004 Aug; 172(2):520-4. PMID: 15247719.
      View in: PubMed
    219. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Aronson WJ. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004 Jun; 171(6 Pt 1):2215-20. PMID: 15126788.
      View in: PubMed
    220. Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, Lue TF. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology. 2004 Jun; 63(6):1148-52. PMID: 15183969.
      View in: PubMed
    221. Hittelman AB, Purohit RS, Kane CJ. Update of staging and risk assessment for prostate cancer patients. Curr Opin Urol. 2004 May; 14(3):163-70. PMID: 15069307.
      View in: PubMed
    222. Freedland SJ, Aronson WJ, Presti JC, Amling CL, Terris MK, Trock B, Kane CJ. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004 Apr 15; 100(8):1633-8. PMID: 15073850.
      View in: PubMed
    223. Freedland SJ, Presti JC, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004 Mar; 63(3):518-22. PMID: 15028449.
      View in: PubMed
    224. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol. 2004 Feb; 171(2 Pt 1):668-71. PMID: 14713783.
      View in: PubMed
    225. Kane CJ, Mitchell JA, Meng MV, Anast J, Carroll PR, Stoller ML. Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes. Urology. 2004 Feb; 63(2):241-6. PMID: 14972462.
      View in: PubMed
    226. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004 Feb 01; 22(3):446-53. PMID: 14691122.
      View in: PubMed
    227. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2003 Dec 01; 98(11):2344-50. PMID: 14635068.
      View in: PubMed
    228. Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, Pasta DJ, Mehta SS, Carroll PR. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003 Dec; 62(6):1035-9. PMID: 14665350.
      View in: PubMed
    229. Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, Carroll PR, Lubeck DP. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. J Urol. 2003 Nov; 170(5):1822-7. PMID: 14532784.
      View in: PubMed
    230. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003 Sep; 170(3):905-8. PMID: 12913727.
      View in: PubMed
    231. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003 Jun; 169(6):2136-41. PMID: 12771735.
      View in: PubMed
    232. Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res. 2003 Jun; 9(6):2121-32. PMID: 12796377.
      View in: PubMed
    233. Freedland SJ, Aronson W, Presti JC, Kane CJ, Terris MK, Elashoff D, Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol. 2003 Jun; 169(6):2142-6. PMID: 12771736.
      View in: PubMed
    234. Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol. 2003 Jun; 169(6):2129-35. PMID: 12771734.
      View in: PubMed
    235. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Terris MK. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2003 Apr; 61(4):742-7. PMID: 12670558.
      View in: PubMed
    236. Yun EJ, Yeh BM, Yabes AP, Coakley FV, Kane CJ. Erdheim-Chester disease: case report and review of associated urological, radiological and histological features. J Urol. 2003 Apr; 169(4):1470-1. PMID: 12629387.
      View in: PubMed
    237. Freedland SJ, Presti JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003 Apr; 61(4):736-41. PMID: 12670557.
      View in: PubMed
    238. Johnstone PA, Riffenburgh RH, Moul JW, Sun L, Wu H, McLeod DG, Kane CJ, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Chung A, Soderdahl D, Do J, Amling CL. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys. 2003 Mar 15; 55(4):964-9. PMID: 12605974.
      View in: PubMed
    239. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003 Mar; 61(3):607-11. PMID: 12639656.
      View in: PubMed
    240. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 2003 Mar; 61(3):589-95. PMID: 12639653.
      View in: PubMed
    241. Freedland SJ, Kane CJ, Presti JC, Terris MK, Amling CL, Dorey F, Aronson WJ. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol. 2003 Mar; 169(3):969-73. PMID: 12576824.
      View in: PubMed
    242. Li LC, Zhao H, Shiina H, Kane CJ, Dahiya R. PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res. 2003 Jan 01; 31(1):291-3. PMID: 12520005; PMCID: PMC165455.
    243. Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol. 2002 Dec; 168(6):2457-60. PMID: 12441939.
      View in: PubMed
    244. Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology. 2002 Nov; 225(2):420-6. PMID: 12409575.
      View in: PubMed
    245. Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ, Dahiya R. Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. J Urol. 2002 Nov; 168(5):2220-6. PMID: 12394763.
      View in: PubMed
    246. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC, Terris MK, Aronson WJ. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002 Oct; 60(4):670-4. PMID: 12385931.
      View in: PubMed
    247. Kane CJ, Tarman GJ, Summerton DJ, Buchmann CE, Ward JF, O'Reilly KJ, Ruiz H, Thrasher JB, Zorn B, Smith C, Morey AF. Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol. 2002 Mar; 167(3):1314-7. PMID: 11832721.
      View in: PubMed
    248. Downs TM, Kane CJ, Grossfeld GD, Meng MV, Carroll PR. Surgery for prostate cancer: rationale, technique and outcomes. Cancer Metastasis Rev. 2002; 21(1):29-44. PMID: 12400995.
      View in: PubMed